Got the big C...

[Sooner or later]

Read up on Tamiflu. It is not as cut and tried as you seem to think.

Also, it is not a substitute for the flu vaccine.

[Chocaholic]

You miss my point.

By choice, I presume.

[Sooner or later]

Originally Posted by Chocaholic

You miss my point.

By choice, I presume.

No, you miss my point. It does not seem to be nearly as effective as you believe. It should be prescribed within 2 days of symptoms. Plenty of side effects. A higher risk compared to reward than initially thought. It might cut one day from how long you have the flu. It might lower the chance of hospitalizations in severe cases. It took decades for pharma to develop Tamiflu as a help for the flu. Covid has been around for about a year.

Tamiflu is not a substitute for the flu vaccine. I would take it if prescribed.

To Tamiflu or Not to Tamiflu? | National Center for Health Research
https://health.clevelandclinic.org/tamiflu-most-effective-if-you-are-at-risk-for-complications/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375804/

[mattdavis11]

Last time I had the flu, I took tamiflu. It did help. There were a bunch of people that got it when I did. We had a conference for work, people came from all over the southern region of the US to meet in Dallas. There were some sick mofos the next few days, one guy died.

[Chocaholic]

But if you get COVID...go home a suffer with it until you can’t breathe anymore.

That’s my point.

[Sooner or later]

Originally Posted by Chocaholic

But if you get COVID...go home a suffer with it until you can’t breathe anymore.

That’s my point.

And we had flu vaccines for 50 years prior to Tamiflu being approved. It can be of benefit though Tamiflu has it's limitations and risks.

There are covid treatments that are allowed that a doctor can use off lable. Some are IV. None have been proven to be game changers.

Pfizer has a "Tamicovid" type pill in trial and could be in use by the end of the year. Others are in the works.

Contrary to Twitter and Facebook we don't have any effective treatments for Covid.

As with the flu vaccine the covid vaccines are the most effective method of disease control.

[pmax]

Originally Posted by Chocaholic

But if you get COVID...go home a suffer with it until you can’t breathe anymore.

That’s my point.

He also missed the excellent point that no treatment, home or clinic based, is offered when you do get the KF.

That OK with you, Sooner ?

[Sooner or later]

https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/#:~:text=Remdesivir%2C%20an%20antiviral%20agent,wh o%20require%20supplemental%20oxygen.

Much more at link.

April 21st, 2021

In outpatients with mild to moderate COVID-19 who are at high risk for disease progression, anti-SARS-CoV-2 antibody-based therapies may have the greatest potential for clinical benefit during the earliest stages of infection. For these patients, the Panel recommends administering bamlanivimab plus etesevimab (AIIa) or casirivimab plus imdevimab (AIIa), both of which are available through Emergency Use Authorizations (EUAs) from the Food and Drug Administration (FDA). See Anti-SARS-CoV-2 Monoclonal Antibodies for more information about using these combinations and other monoclonal antibodies.

Patients With Mild to Moderate COVID-19 Who Are Not Hospitalized
Recommendations
For patients who are not at high risk of disease progression:

The Panel recommends providing supportive care and symptomatic management (AIII).
For patients who are at high risk of disease progression, as defined by the EUA criteria for treatment with anti-SARS-CoV-2 monoclonal antibodies:

The Panel recommends using one of the following combination anti-SARS-CoV-2 monoclonal antibodies (treatments are listed in alphabetical order):
Bamlanivimab 700 mg plus etesevimab 1,400 mg (AIIa); or
Casirivimab 1,200 mg plus imdevimab 1,200 mg (AIIa).
Treatment should be started as soon as possible after the patient receives a positive result on a SARS-CoV-2 antigen test or a nucleic acid amplification test and within 10 days of symptom onset.

Additional Considerations
There are no comparative data to determine whether there are differences in clinical efficacy or safety between bamlanivimab plus etesevimab and casirivimab plus imdevimab.
There are SARS-CoV-2 variants, particularly those that contain the mutation E484K, that reduce the virus’ susceptibility to bamlanivimab and, to a lesser extent, casirivimab and etesevimab in vitro; however, the clinical impact of these mutations is not known.
In regions where SARS-CoV-2 variants with reduced in vitro susceptibility to bamlanivimab plus etesevimab are common, some Panel members would preferentially use casirivimab plus imdevimab while acknowledging that it is not known whether in vitro susceptibility data correlate with clinical outcomes.

[pmax]

Originally Posted by Sooner or later

https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/#:~:text=Remdesivir%2C%20an%20antiviral%20agent,wh o%20require%20supplemental%20oxygen.

Much more at link.

April 21st, 2021

In outpatients with mild to moderate COVID-19 who are at high risk for disease progression, anti-SARS-CoV-2 antibody-based therapies may have the greatest potential for clinical benefit during the earliest stages of infection. For these patients, the Panel recommends administering bamlanivimab plus etesevimab (AIIa) or casirivimab plus imdevimab (AIIa), both of which are available through Emergency Use Authorizations (EUAs) from the Food and Drug Administration (FDA). See Anti-SARS-CoV-2 Monoclonal Antibodies for more information about using these combinations and other monoclonal antibodies.

Patients With Mild to Moderate COVID-19 Who Are Not Hospitalized
Recommendations
For patients who are not at high risk of disease progression:

The Panel recommends providing supportive care and symptomatic management (AIII).
For patients who are at high risk of disease progression, as defined by the EUA criteria for treatment with anti-SARS-CoV-2 monoclonal antibodies:

The Panel recommends using one of the following combination anti-SARS-CoV-2 monoclonal antibodies (treatments are listed in alphabetical order):
Bamlanivimab 700 mg plus etesevimab 1,400 mg (AIIa); or
Casirivimab 1,200 mg plus imdevimab 1,200 mg (AIIa).
Treatment should be started as soon as possible after the patient receives a positive result on a SARS-CoV-2 antigen test or a nucleic acid amplification test and within 10 days of symptom onset.

Additional Considerations
There are no comparative data to determine whether there are differences in clinical efficacy or safety between bamlanivimab plus etesevimab and casirivimab plus imdevimab.
There are SARS-CoV-2 variants, particularly those that contain the mutation E484K, that reduce the virus’ susceptibility to bamlanivimab and, to a lesser extent, casirivimab and etesevimab in vitro; however, the clinical impact of these mutations is not known.
In regions where SARS-CoV-2 variants with reduced in vitro susceptibility to bamlanivimab plus etesevimab are common, some Panel members would preferentially use casirivimab plus imdevimab while acknowledging that it is not known whether in vitro susceptibility data correlate with clinical outcomes.

As already pointed out to you, stay home until you get sicker.



...

[Sooner or later]

I wouldn't expect much treatment for a mild case in a low risk demographic.

If a mild case that is high risk there is a separate protocol. They are not just sent home to get sicker.

More detail can be found here.

https://www.covid19treatmentguidelines.nih.gov/outpatient-management/

[pmax]

Originally Posted by Sooner or later

I wouldn't expect much treatment for a mild case in a low risk demographic.

If a mild case that is high risk there is a separate protocol. They are not just sent home to get sicker.

More detail can be found here.

https://www.covid19treatmentguidelines.nih.gov/outpatient-management/

All patients with dyspnea, oxygen saturation (SpO2) ≤94% on room air at sea level (if this information is available), or symptoms that suggest higher acuity (e.g., chest pain or tightness, dizziness, confusion or other mental status changes) should be referred for an in-person evaluation by a health care provider.

If you don't have those symptoms, stay home until you do get those symptoms.

[Sooner or later]

Originally Posted by pmax

All patients with dyspnea, oxygen saturation (SpO2) ≤94% on room air at sea level (if this information is available), or symptoms that suggest higher acuity (e.g., chest pain or tightness, dizziness, confusion or other mental status changes) should be referred for an in-person evaluation by a health care provider.

If you don't have those symptoms, stay home until you do get those symptoms.

What do you actually want them to do? They don't have a actual fool proof treatment. They ain't gonna put the low risk/mild case in the hospital. They ain't gonna give the low riak/mild case some type medication if it isn't needed at this time.

If a patient reaches a certain point then additional treatment is given. If a patient is at higher risk they are given medication.

Pretty clear cut. The link I posted makes it clear that those in higher risk are not just sent home with no medication.